Esperion Therapeutics, Inc.

NasdaqGM ESPR

Esperion Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -317.00 K

Esperion Therapeutics, Inc. Net Cash Used For Investing Activities is USD -317.00 K for the Trailing 12 Months (TTM) ending September 30, 2024, a -101.03% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Esperion Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 30.71 M, a 200.39% change year over year.
Esperion Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -30.59 M, a -141.29% change year over year.
Esperion Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -12.68 M, a -140.68% change year over year.
Esperion Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 31.16 M, a -70.51% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: ESPR

Esperion Therapeutics, Inc.

CEO	Mr. Sheldon L. Koenig
IPO Date	June 26, 2013
Location	United States
Headquarters	3891 Ranchero Drive
Employees	240
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Insurance Non-Alcoholic Beverages

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Key trends

Past 5 years